Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.56 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 3/20 | 0.50 |
| ▸ | MMP13 | P45452 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27412663 | 0.83 | NPC1 (0.74) | MAPTNPC1RAB9AACHECHRNB2 | |
| SCHEMBL13415305 | 0.82 | ACHE (0.80) | MAPTNPC1RAB9AACHETP53 | |
| SCHEMBL12653007 | 0.81 | NPC1 (0.70) | MAPTNPC1RAB9ACHRNB2CHRNA5 | |
| SCHEMBL6582079 | 0.80 | MAPT (0.61) | MAPTNPC1RAB9ACHRNB2CHRNA5 | |
| SCHEMBL31415475 | 0.78 | ALDH1A1 (0.49) | MAPTNPC1RAB9ATP53LMNA | |
| SCHEMBL28987558 | 0.78 | MAPT (0.43) | MAPTNPC1RAB9AACHECHRNB2 | |
| SCHEMBL30481034 | 0.78 | MAPT (0.43) | MAPTNPC1RAB9AACHECHRNB2 | |
| SCHEMBL8825392 | 0.78 | MAPT (0.58) | MAPTNPC1RAB9ACHRNB2CHRNA5 | |
| SCHEMBL11715801 | 0.78 | NPC1 (0.76) | MAPTNPC1RAB9ACHRNB2CHRNA5 | |
| SCHEMBL16592426 | 0.78 | NPC1 (0.76) | MAPTNPC1RAB9ACHRNB2CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734980-A2 | TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006726-A2 | TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9758480-B2 | 1-(cycloalkyl-carbonyl)proline derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2876105-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-27 | — | — | EP | disclosed |
| EP-2876105-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-05-27 | — | — | EP | disclosed |
| CN-104640843-A | 1-(cycloalkyl-carbonyl)proline derivative | DAINIPPON SUMITOMO PHARMA CO | 2015-05-20 | — | — | CN | disclosed |
| US-20070135442-A1 | Chroman compounds | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| WO-2007053094-A1 | CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135442-A1 | Chroman compounds | CYP3A43, CYP2C9, CYP2C8 | MAPT 3096/4885NPC1 773/4885RAB9A 614/4885 |
| US-20150210640-A1 | 1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE | RB1, F2, SFPQ | MAPT 4798/4885NPC1 4753/4885RAB9A 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.